



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Amsterdam, 23 April 2026
EMADOC-1700519818-3093797
PIP compliance
EMA/VR/0000296756

Statement indicating compliance with the agreed completed paediatric investigation plan

Medicinal product	
Jemperli / Dostarlimab	
Pharmaceutical form(s):	See Annex A of the CHMP Opinion
Strength(s):	See Annex A
Route(s) of administration:	See Annex A
Packaging and package size(s):	See Annex A
Number(s) in the Community Register of Medicinal Products:	See Annex A

Marketing Authorisation Holder (MAH):	
Name and address of the MAH:	GlaxoSmithKline Trading Services Limited 12 River Walk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Procedure	
Procedure number:	EMA/VR/0000296756

Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that:

- the development of this product has complied with all measures in the agreed paediatric investigation plan EMA/PE/0000270085. All studies in the agreed paediatric investigation plan EMA/PE/0000270085 were conducted after the entry into force of that Regulation,



- the Summary of Product Characteristics reflects the results of studies conducted in compliance with this agreed paediatric investigation plan.

In accordance with Article 23a of Regulation (EC) No 1234/2008, this statement indicating compliance with the agreed completed paediatric investigation plan EMA/PE/0000270085 is included in the technical dossier.